Crescent Biopharma
CBIO
49 hedge funds and large institutions have $52.1M invested in Crescent Biopharma in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 11 closing their positions.
1,155% more call options, than puts
Call options by funds: $389K | Put options by funds: $31K
0.01% less ownership
Funds ownership: 0.55% → 0.54% (-0.01%)
11% less funds holding
Funds holding: 55 → 49 (-6)
16% less capital invested
Capital invested by funds: $61.9M → $52.1M (-$9.84M)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$170K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$148K |
| 3 |
Renaissance Technologies
New York
|
+$134K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$57.3K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$43.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$482K |
| 2 |
Two Sigma Advisers
New York
|
-$366K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$248K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
-$176K |
| 5 |
Two Sigma Investments
New York
|
-$119K |
CBIO Hedge Fund Activity: Q3 2023 in Review
49 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2023, worth a combined $52.1M — down 16% from $61.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CBIO and 5 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $170K. The largest seller was Acadian Asset Management, cutting an estimated $482K.
- 49 institutional investors held Crescent Biopharma (CBIO) as of Q3 2023, down from 55 in Q2 2023.
- Funds reported $52.1M of Crescent Biopharma stock for Q3 2023, down 16% quarter-over-quarter.
- 5 funds opened new Crescent Biopharma positions in Q3 2023 and 11 closed out, a net change of -6 holders.
- The largest Crescent Biopharma buyer in Q3 2023 was Vanguard Group, an estimated $170K added.
- The largest Crescent Biopharma seller in Q3 2023 was Acadian Asset Management, an estimated $482K sold.
Based on aggregated 13F filings for Q3 2023.